MK 1775 - AZD1775 | Adavosertib

Based on 20 reference(s) in Google Scholar 80 100 20

Axon 1494

CAS [955365-80-7]

MF C27H32N8O2
MW 500.60

  • Purity: 99%
  • Soluble in 0.1N HCl(aq) and DMSO

MK 1775

Description

A potent and selective Wee1 kinase inhibitor in vitro and in vivo. MK 1775 abolishes cyclin-dependent kinase 1 (CDC2) activity by phosphorylation of the Tyr15 residue. It abrogates a DNA damage checkpoint (G2-phase), leading to apoptosis in combination with several DNA-damaging agents selectively in p53-deficient tumor cell lines. It is under clinical trial for advanced solid tumors.

KEYWORDS: MK 1775 | supplier | Wee1 inhibitor | AZD1775 | Adavosertib | supplier | MK1775 | AZD-1775 | AZD 1775 | CAS [955365-80-7] | CDK1 | Wee1 | Inhibitor | cyclin-dependent kinase 1 | CDC2 | DNA damage | checkpoint | G2-phase | apoptosis | p53-deficient | solid tumor

Order
Size Unit Price Stock
5 mg €80.00 In Stock
25 mg €240.00 In Stock
Special Offers
Size Unit Price Stock
2 x 5 mg €120.00 In Stock
2 x 25 mg €360.00 In Stock
Need more? Bulk Inquiry

The purity of Axon Ligands™ is confirmed by HPLC-MS, 1H-NMR and/or microanalysis. Analytical data are available upon request.

Caution: Axon Ligands™ are not fully tested. They are for research purposes only! Not for human consumption!

Please wait...